Search Results for keywords:"Controlled Substances Act"

The Drug Enforcement Administration (DEA) issued an order to revoke the registration of Dr. Ajumobi Agu in Nevada due to violations of the Controlled Substances Act (CSA). Dr. Agu continued prescribing controlled substances even after his state medical and controlled substances licenses were suspended. The DEA concluded that his actions are inconsistent with the public interest and deemed him untrustworthy to handle such substances. As such, Dr. Agu will be unable to apply to renew or modify his DEA registration, effective May 16, 2025.

In the Federal Register notice titled "Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order," the DEA sought to revoke Dr. Ibrahim Al-Qawaqneh's registration due to his exclusion from federal health care programs after pleading nolo contendere to a charge of offering unlawful Medi-Cal remuneration. Despite being given a chance to defend himself, the DEA found that Dr. Al-Qawaqneh failed to take full responsibility for his actions, which led to doubts about his trustworthiness. Consequently, his DEA Certificate of Registration was revoked to ensure compliance with laws regulating controlled substances.

The Drug Enforcement Administration (DEA) is proposing to place the substance 4-chloromethcathinone (4-CMC) in schedule I of the Controlled Substances Act. This move aims to impose strict regulations similar to other highly controlled drugs, as 4-CMC is known to have a high potential for abuse and no accepted medical use in the U.S. The decision also helps the United States comply with international agreements on psychotropic substances. Public comments on this proposal are accepted until January 29, 2025.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Linwood A. Starks, D.V.M., proposing to revoke his Certificate of Registration because he is not authorized to handle controlled substances in Texas due to the suspension of his veterinary license. Starks requested a hearing but failed to respond to the allegations, leading to a termination of proceedings and his default. As a result, the DEA Administrator decided to revoke his registration and deny any future applications, as maintaining a DEA registration requires state authorization to handle controlled substances. This decision takes effect on April 21, 2025.

The Food and Drug Administration (FDA) is seeking public comments on proposals by the World Health Organization (WHO) to impose international restrictions on several drug substances through treaties. These drugs include Isotonitazene, various synthetic cannabinoids, and benzodiazepines, among others, and are considered for control due to their potential for abuse and lack of recognized therapeutic use. The feedback from the public will help the United States formulate its stance for an upcoming United Nations Commission on Narcotic Drugs meeting. Comments are due by March 22, 2021.

The Drug Enforcement Administration (DEA) temporarily placed a substance called brorphine in Schedule I of the Controlled Substances Act due to its high potential for abuse, lack of accepted medical use, and potential danger to public safety. This action means strict regulatory controls are now in place regarding the manufacturing, distribution, and possession of brorphine. The DEA found brorphine on the illicit market in several countries and associated it with several fatalities in the U.S. Brorphine is a synthetic opioid with effects similar to fentanyl, which poses significant health risks and has been linked to the ongoing opioid epidemic. This temporary scheduling will last for two years and can be extended for an additional year.

The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration of James T. Craig, D.D.S., a dentist from Colorado, meaning he can no longer handle controlled substances. This decision was made because his dental license in Colorado was revoked, and he lacked the necessary state authority to dispense controlled substances. The DEA notified Craig of his right to a hearing, which he opted not to request, resulting in an automatic admission of the allegations against him. Consequently, any pending applications from Craig to renew or modify his registration have also been denied.

The Drug Enforcement Administration (DEA) has issued a final order establishing the adjusted 2024 aggregate production quotas for Schedule I and II controlled substances under the Controlled Substances Act, and the annual needs for certain list I chemicals like ephedrine. This decision was made after considering public comments and relevant factors such as production needs, diversion risks, and quotas set in prior years. DEA strives to ensure that these quotas meet lawful medical and scientific needs while preventing drug misuse. Some public suggestions, like changes to the procurement quota processes or addressing opioid shortage concerns, were noted but found to be outside the scope of this specific order.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Jeffrey W. Young, Jr., a nurse practitioner from Tennessee, due to his lack of state authorization to handle controlled substances. Young's Tennessee nurse and advanced practice nurse licenses were both revoked, making him ineligible to dispense medications under state laws. Despite being given a chance, Young did not request a hearing to challenge this decision, leading the DEA to proceed with the revocation of his Certificate of Registration. This order will be effective from January 29, 2025.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on a new information collection proposal. They aim to revise existing forms (DEA Forms 224 and 224A) to include emergency medical services (EMS) agencies under the Controlled Substances Act. This change would allow EMS agencies to register to handle controlled substances in line with state law. The comment period is open for 30 days, during which people can share their thoughts on the proposal's necessity, accuracy, and possible burden on those required to respond.